Henan Lingrui Pharmaceutical Co Ltd (600285) — Capital Reinvestment Ratio
Henan Lingrui Pharmaceutical Co Ltd (600285) has a Capital Reinvestment Ratio of 0.04x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥140.12 Million) in capital expenditures (CN¥5.61 Million). See Henan Lingrui Pharmaceutical Co Ltd (600285) net asset quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Henan Lingrui Pharmaceutical Co Ltd Capital Reinvestment Ratio (1999–2025)
This chart tracks Henan Lingrui Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. Check 600285 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
Year-by-year Capital Reinvestment Ratio for Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. For live market cap and broader valuation context, see Henan Lingrui Pharmaceutical Co Ltd (600285) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | CN¥553.88 Million | CN¥56.83 Million | ▼ -21.9% |
| 2024 | 0.13x | CN¥875.86 Million | CN¥115.11 Million | ▲ +404.3% |
| 2023 | 0.03x | CN¥813.43 Million | CN¥21.20 Million | ▼ -19.4% |
| 2022 | 0.03x | CN¥834.91 Million | CN¥26.99 Million | ▼ -64.4% |
| 2021 | 0.09x | CN¥845.69 Million | CN¥76.91 Million | ▼ -43.0% |
| 2020 | 0.16x | CN¥450.53 Million | CN¥71.82 Million | ▲ +21.5% |
| 2019 | 0.13x | CN¥450.15 Million | CN¥59.04 Million | ▲ +9.7% |
| 2018 | 0.12x | CN¥436.25 Million | CN¥52.14 Million | ▼ -95.1% |
| 2017 | 2.43x | CN¥105.97 Million | CN¥257.55 Million | ▼ -29.5% |
| 2016 | 3.45x | CN¥63.26 Million | CN¥218.05 Million | ▲ +541.7% |
| 2015 | 0.54x | CN¥156.82 Million | CN¥84.23 Million | ▼ -34.6% |
| 2014 | 0.82x | CN¥124.32 Million | CN¥102.10 Million | ▼ -37.4% |
| 2013 | 1.31x | CN¥127.27 Million | CN¥166.88 Million | ▼ -79.9% |
| 2012 | 6.51x | CN¥15.43 Million | CN¥100.53 Million | ▲ +312.7% |
| 2011 | 1.58x | CN¥40.49 Million | CN¥63.90 Million | ▲ +364.2% |
| 2009 | 0.34x | CN¥132.61 Million | CN¥45.08 Million | ▼ -55.8% |
| 2008 | 0.77x | CN¥43.72 Million | CN¥33.63 Million | ▼ -72.6% |
| 2007 | 2.81x | CN¥15.99 Million | CN¥44.84 Million | ▲ +353.4% |
| 2006 | 0.62x | CN¥26.76 Million | CN¥16.56 Million | ▲ +8.0% |
| 2005 | 0.57x | CN¥33.43 Million | CN¥19.15 Million | ▼ -50.0% |
| 2004 | 1.14x | CN¥35.51 Million | CN¥40.65 Million | ▼ -33.3% |
| 2003 | 1.72x | CN¥23.79 Million | CN¥40.81 Million | ▲ +120.3% |
| 2002 | 0.78x | CN¥69.41 Million | CN¥54.06 Million | ▼ -92.9% |
| 2001 | 10.93x | CN¥3.41 Million | CN¥37.29 Million | ▲ +6.1% |
| 2000 | 10.31x | CN¥3.66 Million | CN¥37.76 Million | ▲ +778.6% |
| 1999 | 1.17x | CN¥4.81 Million | CN¥5.64 Million | — |